Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer

We hope to learn whether tumor genetics and tumor disappearance are related.

a study on Lung Cancer

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis
Dates
study started
estimated completion
Principal Investigator
by Philip C. Mack, PhD (ucdavis)

Description

Summary

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.

Official Title

EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood

Details

OBJECTIVES: - Examine the mutational status of the EGFR pathway in tumor and blood samples from patients with lung cancer. - Correlate the EGFR pathway mutations in these samples with clinical outcomes of these patients. OUTLINE: Archived tumor tissue and blood samples are analyzed via PCR to detect EGFR pathway mutations in DNA.

Keywords

Lung Cancer Lung Neoplasms

Eligibility

For people ages 18 years and up

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed lung cancer

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • May have received prior EGFR inhibitors

Location

  • University of California Davis Cancer Center accepting new patients
    Sacramento California 95817 United States

Lead Scientist at UC Cancer

  • Philip C. Mack, PhD (ucdavis)
    Adjunct Professor, Hematology and Oncology. Authored (or co-authored) 135 research publications.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Davis
ID
NCT00899405
Study Type
Observational
Last Updated